A major limitation in the treatment of disease is the lack of therapeutic selectivity. Recent studies have shown that pathologically altered blood vessels express specific cell surface markers. These markers are detectable by specific homing peptides, which can be used for cell-targeted drug delivery. Tissue-penetrating homing peptides can activate a bulk transport pathway that translocates co-administered substances from the blood vessels into the target tissue. Our lead therapeutic candidate, CARSKNKDC (CAR) peptide, represents a new paradigm in targeted therapy. CAR preferentially homes to, and penetrates, diseased tissue while selectively augmenting the localized efficacy of therapies and accelerating wound healing. CAR can selectively enhance gene therapy, boost drug effectiveness, and reduce systemic side effects by enhancing the efficacy of co-administered therapeutics. This promises to usher in a new age of targeted therapies and disease-specific treatments that are not only more effective than current treatments, but can also reduce, and even eliminate the harmful side effects of current treatments.
CAR peptide applications currently include:
- Learn more about how CAR peptide works
- CAR Peptide Scientific Articles
- For inquiries about CAR peptide and other VBS pharmaceutical products,
please contact us at firstname.lastname@example.org
DISCLAIMER: The material provided on this site is strictly for informational purposes. Do not use this site as a substitute for medical care or medical advice. Please consult with your physician or other medical care provider regarding any medical questions you may have.